BOSTON ~ Boston-based biotech company Liberate Bio. has announced the expansion of its leadership team with the addition of Dr. Shawn Davis as Chief Executive Officer and Dr. Walter R. Strapps as Chief Scientific Officer.

Dr. Davis brings a wealth of experience in drug delivery, diagnostics, and biopharmaceutical development from his time at AstraZeneca and Amgen, where he held multiple roles of increasing responsibility focusing on combination product development, technology strategy, and innovation. He has also provided thought leadership across the industry as a frequent speaker and chair of multiple conferences and as a Subcutaneous Drug Development & Delivery Consortium board member.

Dr. Strapps is an experienced biotech executive who most recently served as Chief Executive Officer of Carver Biosciences, Inc., and currently serves as interim Chief Scientific Officer of Deep Genomics. He has held various roles leading research efforts in oligonucleotide-based therapeutics over the last 20 years at Sirna Therapeutics, Merck & Co., Inc., and Intellia Therapeutics.

More on Boston Chron

• Mayor Wu Announces $1 Million in New Grant Funding to Support the Revitalization of Boston's Restaurant Industry
• Allotex Announces New Investor and Expansion of Production Facilities USA - English USA - English
• Green Office Partner Launches Managed Print Services Program in Canada
• GLCPS Sponsors Two Students to Attend Brown University Leadership Institute
• Vantiva Confirms its Strong Commitment to Diversity, Equity and Inclusion

Commenting on his appointment, Dr. Davis said: "The field of genetic medicines is fascinating, not only for the potential to address the critical needs of patients but also as the next frontier of human medicine... Our ability to rapidly and efficiently design new delivery vehicles has the potential to enable future pharmaceutical partners' pipelines and address previously unreachable biologic targets liberating patients from their genetic disorders."

Liberate Bio was co-founded in 2022 by Drs Michael Mitchell, Stephen Scully, Theresa Reineke, and Nessan Bermingham with a focus on identifying and developing new vehicles to deliver oligonucleotide cargos. With the addition of two experienced leaders in drug delivery technology to its team, Liberate Bio is well positioned to make significant progress towards its goal of providing innovative solutions for genetic medicine treatments.

---

Show All News | Report Violation